Navigation Links
New Anti-Clotting Drug May Cut Brain Bleeding Risk: Study
Date:2/2/2012

THURSDAY, Feb. 2 (HealthDay News) -- A new medication that helps prevent strokes in people with the abnormal heart rhythm disorder known as atrial fibrillation poses less risk of bleeding in the brain than a commonly used drug, research comparing rivaroxaban (Xarelto) and warfarin suggests.

Anti-clotting medications, also called blood-thinners or anticoagulants, include warfarin (Coumadin) and aspirin, among others. In patients with atrial fibrillation, these drugs can reduce the risk of ischemic stroke, which occurs when a vessel becomes clogged by a blood clot. But the drugs can also cause excessive bleeding because they make it harder for blood to clot.

In a new study, researchers led by Dr. Graeme Hankey, a neurologist at the Royal Perth Hospital and University of Western Australia, followed more than 14,000 people who took anti-clotting drugs for a median of two years. Of those patients, 136 had bleeding in the brain.

People who took a new anticoagulant called rivaroxaban (Xarelto) -- and suffered from the most common type of atrial fibrillation and didn't have heart valve damage -- were about one-third less likely to experience bleeding in the brain than those who took warfarin, the investigators found.

So which drug is best?

In the big picture, "all of the newer [blood-thinning] drugs are reported to have lower intracranial bleeding risks than Coumadin [warfarin] when used in the setting of atrial fibrillation to prevent stroke," said Dr. Ken Uchino, program director of the Vascular Neurology Fellowship at the Cleveland Clinic's Cerebrovascular Center, who was not involved with the study but is familiar with the findings.

"This is one advantage, but in absolute terms it is small -- on average going from 0.7 percent per year of intracranial bleeding risks to 0.5 percent per year for rivaroxaban -- though this is a 33 percent decrease for rivaroxaban," Uchino explained.

The new drugs are more convenient than warfarin, which requires the administration of blood tests to make sure patients are getting the proper doses. But "there have been concerns about unanticipated risks and how the new medications are all short-acting -- what happens if one misses doses? -- and cleared by the kidneys -- what happens if the kidneys start to fail without anyone knowing?" Uchino said.

Also, the newer anti-clotting drugs are expensive.

The study, which was funded by Johnson & Johnson and Bayer HealthCare, was slated for presentation Thursday at the American Stroke Association's International Stroke Conference, in New Orleans.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about stroke.

-- Randy Dotinga

SOURCES: Ken Uchino, M.D., program director, Vascular Neurology Fellowship, Cerebrovascular Center, Cleveland Clinic, Ohio; American Stroke Association, news release, Feb. 2, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
2. Extended use of anti-clotting drug helps some bedridden patients
3. New Anti-Clotting Drug May Work Better After Hip Replacement
4. Anti-clotting agent does not improve outcomes of patients with severe pneumonia
5. Anti-Clotting Drug May Cause Severe Bleeding With No Benefit
6. Analysis does not support genetic test before use of anti-clotting drug
7. Gadgets not related to teenagers brain pain
8. Dementia Rates Escalate as Brain Capacity Diminishes with Age
9. Researchers discover new way to kill pediatric brain tumors
10. Scientists Pinpoint Area of Brain That Fears Losing Money
11. Physical Changes in Brain Linked to Altered Spirituality
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Anti-Clotting Drug May Cut Brain Bleeding Risk: Study
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Mediaplanet is ... Wound Care" campaign in USA Today, which will educate readers on how to take ... the campaign, a large focus is placed on melanoma. Dancing with the Stars professional, ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “When the Stars ... Home” is the creation of published author Laura Weigel Douglas, an avid reader who ... in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t be ...
(Date:5/26/2017)... ... , ... Water damage to the flooring of several classrooms at The Fort ... with a number of critical issues to address before students could return to classes. ... little or no disruption to class schedules. Second, the project had to comply with ...
Breaking Medicine News(10 mins):
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: